BiotechTube

Tadalafil

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia

Trial Timeline

Jul 1, 2010 → Apr 1, 2011

NCT ID
NCT01183650

About Tadalafil

Tadalafil is a phase 1 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01183650. Target conditions include Benign Prostatic Hyperplasia.

What happened to similar drugs?

8 of 20 similar drugs in Benign Prostatic Hyperplasia were approved

Approved (8) Terminated (3) Active (9)
🔄Tadalafil + PlaceboEli LillyPhase 3
🔄5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
🔄Placebo + tadalafilEli LillyPhase 3
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
🔄Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (13)

NCT IDPhaseStatus
NCT02252367ApprovedCompleted
NCT02224846ApprovedCompleted
NCT01326117ApprovedWithdrawn
NCT01324999Phase 2/3Completed
NCT01183650Phase 1Completed
NCT01066845Pre-clinicalCompleted
NCT00822354Pre-clinicalCompleted
NCT00157326Phase 2Completed
NCT00333281ApprovedCompleted
NCT00422578ApprovedCompleted
NCT00421083Phase 3Completed
NCT00547417Phase 3Completed
NCT00547599ApprovedCompleted

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
ASP4901 + Tamsulosin + PlaceboAstellas PharmaPhase 2
35
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
39
Tadalafil + PlaceboEli LillyPhase 2
35
Tadalafil + Placebo + TamsulosinEli LillyPhase 3
40
Tadalafil 2.5 mg + Tadalafil 5 mg + PlaceboEli LillyPhase 2
35
Tadalafil 5 mg + Placebo tablet + Tamsulosin + Placebo capsuleEli LillyPhase 3
40
Tadalafil + PlaceboEli LillyPhase 3
40
Tadalafil + Placebo + TamsulosinEli LillyPhase 2
35
Tadalafil + PlaceboEli LillyPhase 3
40
tadalafil + tadalafil + tadalafil + tadalafil + placeboEli LillyPhase 2/3
38
Tadalafil + Placebo + FinasterideEli LillyPhase 3
40